<?xml version="1.0" encoding="UTF-8"?>
<p>Several other potential drugs include BCR‐ABL kinase inhibitor imatinib and Type‐II transmembrane serine protease (TMSPSS2) inhibitors.
 <xref rid="rmv2113-bib-0044" ref-type="ref">
  <sup>44</sup>
 </xref> Imatinib inhibits the fusion of virions with the endosomal membrane and as such possesses anti‐coronavirus activity.
 <xref rid="rmv2113-bib-0045" ref-type="ref">
  <sup>45</sup>
 </xref> A drug screening research team led by The Shanghai Tech University and Shanghai Institute of Materia Medica recently reported 30 agents with potential antiviral activity against SARS‐CoV‐2.
 <xref rid="rmv2113-bib-0046" ref-type="ref">
  <sup>46</sup>
 </xref> These agents include remdesivir, saquinavir, indinavir, ritonavir, lopinavir, darunavir, fosamprenavir, carfilzomib, presatovir, atazanavir, enzaplatovir, tipranavir, maribavir, abacavir, bortezomib, raltegravir, elvitegravir, deoxyrhapontin, montelukast, polydatin, disulfiram, chalcone, ebselen, tideglusib, carmofur, PX12, shikonin, TDZD‐8, cinanserin, and cyclosporin A. Also, some Chinese herbal medicines such as Radix Sophorae Tonkinensis and Rhizoma Polygoni Cuspidati were found to possess activity against SARS‐CoV‐2.
 <xref rid="rmv2113-bib-0046" ref-type="ref">
  <sup>46</sup>
 </xref>
</p>
